Innovative Therapeutics BioAegis specializes in developing plasma gelsolin-based therapies aimed at severe inflammatory and infectious diseases such as sepsis, ARDS, and Multiple Organ Failure, presenting opportunities to supply advanced biologics to hospitals and critical care centers.

Strategic Collaborations Partnerships with the University of Texas System and programs like BARDA indicate a focus on government and institutional contract opportunities to accelerate product development and secure funding for clinical trials.

Regulatory Engagement Ongoing developments and clinical-stage programs suggest potential for early engagement with regulatory agencies to facilitate product approval pathways for innovative treatments.

Research Expansions With recent presentations at biotech investor events and continued R&D efforts, there are openings for collaborations and licensing agreements to expand technology reach and co-develop new indications.

Funding and Growth Having raised $22 million and maintaining revenue in the $10-25 million range, BioAegis is positioned for growth, creating opportunities for partners and investors focused on innovative biotech solutions in inflammation and infection.